COMP <GO>
IART vs MRK // RETURN ON INVESTED CAPITAL (ROIC)
Integra LifeSciences Holdings Corporation (NASDAQ) VS. Merck & Company Inc. (NYSE) • 15-METRIC TALLY: IART 1
— MRK 10
▲ RETURN ON INVESTED CAPITAL (ROIC) LEADER: MRK
LAST: $12.83 (+4.82%) • MKT CAP: $998.2M
roic
-35.00%
LAST: $146.33 (+3.83%) • MKT CAP: $361.02B
roic
20.70%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (IART VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | IART | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 50.90% | 74.80% | -23.90 | MRK | /gross-margins <GO> |
| Return on Invested Capital (ROIC) ACTIVE | -35.00% | 20.70% | -55.70 | MRK | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 15.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -3.11% | 3.42% | -6.53 | MRK | /fcf-yield <GO> |
| Operating Margin | -30.20% | 34.30% | -64.50 | MRK | /operating-margins <GO> |
| Net Profit Margin | -31.60% | 28.10% | -59.70 | MRK | /net-margins <GO> |
| Revenue Growth (YoY) | 1.50% | 1.30% | +0.20 | IART | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.26% | -2.26 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.64 | 5.19 | -4.55 | MRK | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | 7/9 | -3.00 | MRK | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 43.7 | 51.7 | -8.00 | MRK | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.92 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 18.4x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $998.2M | $361.02B | -$360.02B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | IART REV | MRK REV | IART GROSS % | MRK GROSS % | IART FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $1.64B | $65.01B | 50.9% | 74.8% | -$31.1M | $12.36B |
| FY 2024 | $1.61B | $64.17B | 54.8% | 76.3% | $25.0M | $18.10B |
| FY 2023 | $1.54B | $60.12B | — | — | $140.0M | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
IART // BETA —
MRK // BETA 0.92